Ken Griffin Corvus Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$1.36 - $2.29 $9,384 - $15,801	-6,900 Reduced 46.31%	8,000 $14,000
Q1 2024 May 15, 2024	BUY	$1.76 - $2.41 $11,968 - $16,388	6,800 Added 83.95%	14,900 $26,000
Q4 2023 Feb 14, 2024	SELL	$1.08 - $1.92 $25,056 - $44,544	-23,200 Reduced 74.12%	8,100 $14,000
Q3 2023 Nov 14, 2023	SELL	$1.41 - $2.97 $11,421 - $24,057	-8,100 Reduced 20.56%	31,300 $45,000
Q2 2023 Aug 14, 2023	BUY	$1.0 - $3.86 $39,400 - $152,084	39,400 New	39,400 $90,000
Q4 2022 Feb 14, 2023	SELL	$0.74 - $1.04 $888 - $1,248	-1,200 Reduced 9.76%	11,100 $9,000
Q3 2022 Nov 14, 2022	SELL	$0.71 - $1.17 $9,301 - $15,326	-13,100 Reduced 51.57%	12,300 $10,000

27.8M

22.9K

29.8K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $409M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.